GR900100653A - Νευροτροφικός παράγοντας που προέρχεται από τον εγκέφαλο. - Google Patents

Νευροτροφικός παράγοντας που προέρχεται από τον εγκέφαλο.

Info

Publication number
GR900100653A
GR900100653A GR900100653A GR900100653A GR900100653A GR 900100653 A GR900100653 A GR 900100653A GR 900100653 A GR900100653 A GR 900100653A GR 900100653 A GR900100653 A GR 900100653A GR 900100653 A GR900100653 A GR 900100653A
Authority
GR
Greece
Prior art keywords
bdnf
nucleic acid
ngf
acid sequences
relates
Prior art date
Application number
GR900100653A
Other languages
English (en)
Other versions
GR1002052B (en
Inventor
Ralph Alberson
Yves-Alain Barde
Ervin Friedrich Hans Hoenen
Magdalena Hofer
Andreas Hohn
Carolyn Hyman
M Ronald Lindsay
Friedrich Lottspeich
George Yancopoylos
Original Assignee
Max Planck Gesellschaft
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Regeneron Pharma filed Critical Max Planck Gesellschaft
Publication of GR900100653A publication Critical patent/GR900100653A/el
Publication of GR1002052B publication Critical patent/GR1002052B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε αλληλουχίες νουκλεϊκού οξέος που κωδικοποιούν για νευροτροφικό παράγοντα που προέρχεται από τον εγκέφαλο (BDNF), όπως επίσης σε πρωτεϊνη BDNF που παράγεται σε ποσότητες χρησιμοποιώντας αυτές τις αλληλουχίες νουκλεϊκού οξέος, όπως επίσης σε κομμάτια και παράγωγα της. Επιπλέον η εφεύρεση αναφέρεται σε φαρμακολογικές συνθέσεις και θεραπευτικές χρήσεις του BDNF, έχοντας παρέξει για πρώτη φορά, τα μέσα για την παραγωγή επαρκών ποσοτήτων ουσιαστικά καθαρού BDNF για κλινική χρήση. Σε μια ειδική ενσωμάτωση ο ΒDNF μπορεί να χρησιμοποιηθεί για την προαγωγή της επιβίωσης των ντοπαμινεργικών νευρώνων της μελαίνης ουσίας και των χολινεργικών νευρώνων βασικού προσεγκεφάλου, με τον τρόπο αυτό παρέχοντας μια μέθοδο για την θεραπεία, αντίστοιχα, της νόσου του Parkinson και της νόσου του Alzheimer. Η εφεύρεση επίσης αναφέρεται σε αντισώματα που στρέφονται κατά BDNF ή κομματιών του, έχοντας παρέξει μια μέθοδο για την παραγωγή επαρκούς ανοσογόνου. Επιπλέον, επιτρέποντας μια σύγκριση μεταξύ των αλληλουχιών νουκλεϊκού οξέος των BDNF και NGF, η παρούσα εφεύρεση προβλέπει για την ταυτοποίηση ομόλογων περιοχών αλληλουχίας νουκλεϊκού οξέος μεταξύ BDNF και NGF, με τον τρόπο αυτό ορίζοντας μια BDNF/NGF γονιδιακή οικογένεια: η εφεύρεση παρέχει μια μέθοδο για την ταυτοποίηση και απομόνωση επιπλέον μελών αυτής της γονιδιακής οικογένειας. ω
GR900100653A 1989-08-30 1990-08-30 Alimentary influence agent of the nerves coming from the brain GR1002052B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/400,591 US5180820A (en) 1989-08-30 1989-08-30 Brain-derived neurotrophic factor

Publications (2)

Publication Number Publication Date
GR900100653A true GR900100653A (el) 1991-12-30
GR1002052B GR1002052B (en) 1995-11-20

Family

ID=23584217

Family Applications (1)

Application Number Title Priority Date Filing Date
GR900100653A GR1002052B (en) 1989-08-30 1990-08-30 Alimentary influence agent of the nerves coming from the brain

Country Status (8)

Country Link
US (2) US5180820A (el)
JP (1) JP2783450B2 (el)
CZ (1) CZ285649B6 (el)
DD (2) DD299196A5 (el)
GR (1) GR1002052B (el)
LT (2) LT4011B (el)
RU (2) RU2131926C1 (el)
ZA (2) ZA906926B (el)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709837B1 (en) * 1989-03-10 2004-03-23 Takeda Chemical Industries, Inc. Polypeptide and production thereof
US6933276B1 (en) 1989-08-30 2005-08-23 Regeneron Pharmaceuticals, Inc. Methods of treating peripheral neuropathies using neurotrophin-3
US6780837B1 (en) * 1989-08-30 2004-08-24 The Regents Of The University Of California Prevention of retinal injury and degeneration by specific factors
US6174701B1 (en) * 1989-12-12 2001-01-16 Genentech, Inc. Neuronal factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5986070A (en) * 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
US5606031A (en) * 1990-04-06 1997-02-25 Lile; Jack Production and purification of biologically active recombinant neurotrophic protein in bacteria
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
FR2671487B1 (fr) * 1991-01-14 1993-03-19 Oreal Utilisation d'un facteur de croissance dans une composition amincissante.
WO1995012982A1 (en) * 1993-11-09 1995-05-18 The Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogeneous neuronal cell transplants
US5175103A (en) * 1991-10-21 1992-12-29 Trustees Of University Of Pennsylvania Preparation of pure cultures of post-mitotic human neurons
US5792900A (en) * 1991-10-21 1998-08-11 The Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants
DK0632008T3 (da) * 1993-06-01 1998-09-23 Ono Pharmaceutical Co Pentansyrederivater
US5602309A (en) * 1993-10-04 1997-02-11 University Of Kentucky Research Foundation Transgenic mice which overexpress nerve growth factor
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
WO1996014834A1 (en) * 1994-11-10 1996-05-23 University Of Kentucky Research Foundation Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
CZ300296B6 (cs) 1996-11-15 2009-04-15 Genentech, Inc. Zpusob izolace rekombinantního lidského neurotrofinu, neurotrofinový prostredek a zpusob cištení neurotrofinu
CA2277955A1 (en) 1997-01-23 1998-07-30 Michiko Kishino Remedies for diabetes
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
US6391544B1 (en) * 1998-05-15 2002-05-21 Abbott Laboratories Method for using unequal primer concentrations for generating nucleic acid amplification products
ATE406907T1 (de) * 1998-10-28 2008-09-15 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
JP2000169389A (ja) * 1998-12-08 2000-06-20 Sumitomo Pharmaceut Co Ltd 触覚異常治療剤
US7037493B2 (en) 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
AU2001278981A1 (en) * 2000-07-21 2002-02-05 Tom F Lue Prevention and treatment of sexual arousal disorders
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
EP1373905A2 (de) * 2001-04-06 2004-01-02 BioVisioN AG Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien
WO2003070189A2 (en) * 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
ES2537015T3 (es) 2003-03-19 2015-06-01 Biogen Ma Inc. Proteína de unión del receptor de NOGO
EP1500399A1 (en) * 2003-07-24 2005-01-26 Institut Pasteur Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
AU2004294178C1 (en) * 2003-11-19 2011-10-27 Rules-Based Medicine, Inc. Methods for diagnosis, stratification, and monitoring of Alzheimer's disease
CA2562024C (en) 2004-04-07 2014-05-27 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US7037698B2 (en) 2004-05-19 2006-05-02 Amano Enzyme Inc. Pyrroloquinoline quinone-dependent glucose dehydrogenase
EP1776136B1 (en) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Treatment of conditions involving demyelination
BRPI0613387A2 (pt) 2005-07-08 2011-01-11 Biogen Idec Inc anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
CA2661042C (en) * 2006-08-18 2012-12-11 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
CA2669800C (en) * 2006-11-17 2013-08-20 The Research Foundation For Microbial Diseases Of Osaka University Nerve elongation promoter and elongation inhibitor
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
EP2217697B1 (en) * 2007-11-08 2015-06-10 Biogen MA Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
US20100112565A1 (en) * 2008-11-03 2010-05-06 Life Technologies Corporation Methods, kits, and reaction mixtures for high resolution melt genotyping
US20100112557A1 (en) * 2008-11-03 2010-05-06 Applied Biosystems Inc. Method for high resolution melt genotyping
WO2010079850A2 (en) 2009-01-12 2010-07-15 Takeda Pharmaceutical Company Limited Agent for prophylaxis or treatment of cancer
CA2752237C (en) * 2009-02-12 2020-03-24 Opko Curna, Llc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
JP5873003B2 (ja) 2009-03-18 2016-03-01 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
EP4273164A3 (en) 2009-10-09 2024-01-24 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
KR20120089743A (ko) * 2009-11-09 2012-08-13 제네포드 테라퓨틱스 에이비 생체 내에서 최적화된 뉴런 특이적 연속 도파 합성을 위한 신규한 바이러스 벡터 구성물
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9149427B2 (en) 2010-12-02 2015-10-06 Neurotech Usa, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
ES2983576T3 (es) 2011-12-02 2024-10-23 Armagen Inc Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC
EP2825648B1 (en) * 2012-03-15 2018-09-05 CuRNA, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
EP3242893A1 (en) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
EP3302524B1 (en) 2015-05-27 2020-09-23 Neurotech USA, Inc. Use of encapsulated cell therapy for treatment of glaucoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213963A1 (de) * 1982-04-15 1983-10-27 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neurotropher faktor
WO1991003569A1 (en) * 1989-08-30 1991-03-21 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Neurotrophin-3, a novel neurotrophic factor related to nerve growth factor and brain derived neurotrophic factor
EP0450386A2 (en) * 1990-04-06 1991-10-09 Synergen, Inc. Production of biologically active, recombinant members of the NGF/BDNF family of neurotrophic proteins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
DK161152C (da) * 1983-03-03 1991-11-11 Genentech Inc Polypeptid med egenskaber som human beta-nervevaekstfaktor og fremgangsmaade til fremstilling deraf, dna-isolat omfattende en sekvens som koder for polypeptidet, replicerbar udtrykkelsesvektor for dna-sekvensen, rekombinant vaertscelle transformeret med vektoren, farmaceutisk praeparat indeholdende polypeptidet og fremg. der omfatter anvendelsen af polypeptidet til fremst. af et farmaceutisk praeparat
US4935370A (en) * 1983-12-23 1990-06-19 Pfizer Inc. Expression plasmids for improved production of heterologous protein in bacteria
US4758512A (en) * 1984-03-06 1988-07-19 President And Fellows Of Harvard College Hosts and methods for producing recombinant products in high yields
US4680262A (en) * 1984-10-05 1987-07-14 Genentech, Inc. Periplasmic protein recovery
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
CA1310602C (en) * 1986-06-03 1992-11-24 Hajime Horii Yeast promoter and process for preparing heterologous protein
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
EP0347435A4 (en) * 1987-09-04 1991-11-21 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins
IT1219874B (it) * 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5272063A (en) * 1988-11-22 1993-12-21 Syntex (U.S.A.) Inc. Process of making human nerve growth factor
EP0448605A4 (en) * 1988-12-15 1991-11-21 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
US6709837B1 (en) * 1989-03-10 2004-03-23 Takeda Chemical Industries, Inc. Polypeptide and production thereof
JP2877509B2 (ja) * 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
DK0414151T3 (da) * 1989-08-21 1995-05-22 Takeda Chemical Industries Ltd Humane nervevæskstfaktorproteiner og fremstilling deraf
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
ES2093112T3 (es) * 1990-09-25 1996-12-16 Genentech Inc Nuevo factor neurotrofico.
US7020718B2 (en) 2000-05-15 2006-03-28 Hewlett-Packard Development Company, L.P. System and method of aggregating discontiguous address ranges into addresses and masks using a plurality of repeating address blocks

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213963A1 (de) * 1982-04-15 1983-10-27 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neurotropher faktor
WO1991003569A1 (en) * 1989-08-30 1991-03-21 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Neurotrophin-3, a novel neurotrophic factor related to nerve growth factor and brain derived neurotrophic factor
EP0450386A2 (en) * 1990-04-06 1991-10-09 Synergen, Inc. Production of biologically active, recombinant members of the NGF/BDNF family of neurotrophic proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CLAIMS NOT SEARCHED: 54-63,86,105-113,118-123 *
CLAIMS SEARCHED: 1-53,64-85,87-104,114-117 *
NATURE, vol. 331, 21st January 1988, pages 261-262; M.M. HOFER et al.: "Brain-derived neurotrophic factor prevents neuronal death in vivo" *
NATURE, vol. 341, 14th September 1989, pages 149-152; J. LEIBROCK et al.: "Molecular cloning and expression of brain-derived neurotrophic factor" *
SCIENCE, vol. 239, March 1988, pages 1288-1291; C.C. LEE et al.: "Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase" *
THE EMBO JOURNAL, vol. 1, no. 5, 1982, pages 549-553; Y.-A. BARDE et al.: "Purification of a new neurotrophic factor from mammalian brain" *

Also Published As

Publication number Publication date
US5180820A (en) 1993-01-19
DD299197A5 (de) 1992-04-02
GR1002052B (en) 1995-11-20
DD299196A5 (de) 1992-04-02
CZ422990A3 (cs) 1999-06-16
LT4063B (en) 1996-11-25
LTIP1818A (en) 1995-09-25
JPH05328974A (ja) 1993-12-14
RU2131926C1 (ru) 1999-06-20
JP2783450B2 (ja) 1998-08-06
LT4011B (en) 1996-08-26
RU2128226C1 (ru) 1999-03-27
ZA906926B (en) 1991-06-26
LTIP1546A (en) 1995-07-25
CZ285649B6 (cs) 1999-10-13
US5453361A (en) 1995-09-26
ZA906927B (en) 1991-06-26

Similar Documents

Publication Publication Date Title
GR900100653A (el) Νευροτροφικός παράγοντας που προέρχεται από τον εγκέφαλο.
ES2098271T3 (es) Factor neurotrofico derivado del cerebro.
LV10308A (lv) Ciliarais neirotropais faktors
HU905333D0 (en) Process for producing cyclic amino-acid derivatives
DE69941059D1 (de) Nukleotid- und proteinsequenzen von nogo-genen und darauf beruhende methoden
SI0852585T1 (en) Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product
EP0458673A1 (en) Growth-inhibitory factor and cDNA coding for growth inhibitory factor
MX9203350A (es) Receptor de hormona foliculo estimulante humana.
CA2047718A1 (en) Purified ciliary neurotrophic factor
PT84384A (en) Process for preparing isohexide nucleosides useful as medicaments
GR900100691A (el) Νευροτροφικός παράγοντας ακτινωτού.
SU833225A1 (ru) Способ лечени шейного остеохондроза
Barde et al. Brain derived neurotrophic factor
IT1265305B1 (it) Derivati metallorganici degli acidi s-acil-2-(s)-(2-pirrolidon-5-(s)- carbonilamido)-3-mercapto propionici con selenio, procedimento per la
ATA249789A (de) Verfahren zur herstellung neuer verbindungen sowie verwendung desselben

Legal Events

Date Code Title Description
MA Right expired